Guggenheim Capital
TSHA icon

Guggenheim Capital’s Taysha Gene Therapies TSHA Stock Holding History

Guggenheim Capital’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$202K Buy
29,721
+13,136
+79% +$77.7K ﹤0.01% 1647
2026
Q1 		$74.1K Buy
16,585
+5,474
+49% +$25.5K ﹤0.01% 1586
2025
Q4 		$61.1K Buy
+11,111
New +$54K ﹤0.01% 1734

Other funds holding TSHA

Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Guggenheim Capital's TSHA Position: Q2 2026 in Review

Guggenheim Capital increased its Taysha Gene Therapies (TSHA) stake by 79% in Q2 2026, buying an estimated $77.7K and bringing the position to 29,721 shares worth $202K. The position accounts for ﹤0.01% of the portfolio, ranked #1647.

Guggenheim Capital first reported a position in TSHA in Q4 2025 and has held it in 3 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Guggenheim Capital held 29,721 shares of Taysha Gene Therapies worth $202K as of Q2 2026.
  • Guggenheim Capital bought 13,136 Taysha Gene Therapies shares in Q2 2026, an estimated $77.7K.
  • Taysha Gene Therapies made up ﹤0.01% of Guggenheim Capital's portfolio in Q2 2026, its #1647 holding.
  • Guggenheim Capital first reported a position in Taysha Gene Therapies in Q4 2025 and has held it in 3 quarters since.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.